Back to News
Market Impact: 0.22
Diasome Pharmaceuticals to Present HDV-Insulin Phase 2b Clinical Data at EASD 2026 and Inaugural Breakthrough T1D Clinical & Research Congress
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
Phase 2b OPTI-2 findings will be presented showing that HDV-insulin lispro may maintain glycemic control while reducing hypoglycemia in adults with type 1 diabetes. The results are clinically encouraging but remain mid-stage trial evidence, with no efficacy statistics, regulatory milestones, or commercialization details provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Tesla will stop making the Cybertruck in 2027
- Globus Medical stock holds at Neutral as BTIG cites revenue miss
- Canaccord reiterates Natera stock rating on strong Q3 results
- Tesla to wind down Cybertruck production at Texas gigafactory next year, Musk says